Key result
Resveratrol administration at /kg/day attenuated transverse aortic constriction-induced adverse cardiac systolic and diastolic function, fibrosis, inflammation, and oxidative stress.
Why the study?
While resveratrol protects against pressure-overload-induced cardiac hypertrophy and contractile dysfunction, its effect on cardiac fibrosis and diastolic function remained unclear.
In a mouse model of pressure overload, high-dose resveratrol attenuated cardiac fibrosis and diastolic dysfunction by inhibiting PTEN degradation.
Answers are grounded in this paper and cite their sources.
Supports further resveratrol study in pressure-overload models; leaves open human translation and clinical relevance.
Scope Cardiac fibrosis is a key feature of cardiac remodeling. Recently, a protective role for resveratrol (RES) in pressure‐overload‐induced cardiac hypertrophy and contractile dysfunction has been demonstrated. However, the effect of RES on cardiac fibrosis and diastolic function in this model remains unclear. Methods and results Cardiac remodeling is induced in mice by transverse aortic constriction (TAC) for 2–4 weeks. RES is administered at dose of 5 or 50 mg kg –1 d –1 for 2 weeks. It is found that RES administration at 50 mg kg –1 d –1 significantly attenuates TAC‐induced adverse cardiac systolic and diastolic function, fibrosis, inflammation, and oxidative stress via inhibiting PTEN degradation and the downstream mediators. However, RES at 5 mg kg –1 d –1 has no significant effects. RES at 50 mg kg –1 d –1 also ameliorates pre‐established adverse cardiac function and remodeling induced by TAC. Treatment with PTEN inhibitor VO‐OHpic (10 mg kg –1 d –1 ) for 2 weeks abolishes RES‐mediated protective effects. Additionally, the effect of RES (100 µ m ) on inhibition of Ang II‐induced fibroblast proliferation and activation in vitro is verified. Conclusions The findings provide new evidence that RES plays a critical role in the progression of cardiac fibrosis and diastolic dysfunction, and suggest that RES may be a promising therapeutic agent for cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2019) studied Cardiac fibrosis and diastolic dysfunction. Resveratrol was evaluated on Cardiac systolic and diastolic function, fibrosis, inflammation, and oxidative stress. Resveratrol administration at /kg/day attenuated transverse aortic constriction-induced adverse cardiac systolic and diastolic function, fibrosis, inflammation, and oxidative stress.
Synapse has enriched 10 related papers. Consider them for comparative context: